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ABSTRACT
◥
Purpose: Pembrolizumab demonstrated efficacy in PD-L1–pos-
itive [combined positive score (CPS) ≥1] advanced gastric/gastro-
esophageal junction (G/GEJ) cancer in the first-, second-, and third-
line setting in KEYNOTE-062, KEYNOTE-061, and KEYNOTE-
059, respectively. To better delineate the specificity of CPS as a
predictor of clinical outcomes, we analyzed pembrolizumab efficacy
in patients with CPS ≥ 10 in these trials.
Patients and Methods: Included were patients with CPS ≥ 10
tumors from KEYNOTE-059 cohort 1 (pembrolizumab, n ¼ 46;
post hoc), KEYNOTE-061 (pembrolizumab, n¼ 53; chemotherapy,
n ¼ 55; post hoc), and KEYNOTE-062 (pembrolizumab, n ¼ 92;
chemotherapy, n ¼ 90; primary). Efficacy outcomes were overall
survival (OS), progression-free survival (PFS), objective response
rate (ORR), and duration of response (DOR).
Results: In KEYNOTE-059, median follow-up was 6 months,
median OS was 8 months [95% confidence interval (CI), 5.8–11.1],
ORR was 17%, and median (range) DOR was 21 months (3þ to
35þ). In KEYNOTE-061, median follow-up was 9 months, median
OS (pembrolizumab vs. chemotherapy) was 10 versus 8 months
(HR, 0.64; 95% CI, 0.41–1.02), median PFS was 3 months versus
3 months (HR, 0.86; 95% CI, 0.56–1.33), ORR was 25% versus 9%,
andmedian (range)DORwas not reached (4 to 26þmonths) versus
7 months (3–7). In KEYNOTE-062, median follow-up was
11 months, median OS (pembrolizumab vs. chemotherapy) was
17months versus 11months (HR, 0.69; 95%CI, 0.49–0.97), median
PFS was 3 months versus 6 months (HR, 1.09, 95% CI; 0.79–1.49),
ORRwas 25% versus 38%, andmedian (range) DORwas 19months
(1þ to 34þ) versus 7 months (2þ to 30þ).
Conclusions: This comprehensive analysis showed consistent
improvements toward more favorable clinical outcomes with pem-
brolizumab across lines of therapy in patients with CPS ≥ 10 G/GEJ
cancer.
Introduction
Gastric cancer ranks fifth among the most commonly diagnosed
cancers worldwide and accounts formore than 1million new cases and
approximately 800,000 deaths per year (1). Evidence suggests that the
programmed death 1 (PD-1) pathway may have prognostic signifi-
cance in gastric cancer, with several studies demonstrating a relation-
ship between expression of PD-L1 and overall survival (OS; refs. 2–4).
Although the prevalence of immunohistochemical PD-L1 expression
varies between studies, most indicate that a significant proportion
(range, 25%–65%) of patients with gastric cancer overexpress PD-L1,
regardless of scoring method (2, 5). Current first-line standard-of-care
therapy for patients with unresectable locally advanced recurrent or
metastatic disease remains combination chemotherapy with a fluor-
opyrimidine and a platinum-based agent, with trastuzumab added to
the regimen for patients with HER2-positive disease (6). Various
agents are recommended for use in second-line therapy, including
chemotherapies and immunotherapies. The anti–PD-1 inhibitor pem-
brolizumab is approved for the treatment of patients with gastric
cancer and is among the preferred regimens as second-line therapy for
patients with microsatellite instability-high (MSI-H) or mismatch
1Department of the Division of Hematology Oncology, David Geffen School of
Medicine at UCLA, Los Angeles, California. 2Department of Medical Oncology,
Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut. 3Depart-
ment of Medical Oncology, Vall d’Hebron Hospital Campus and Institute of
Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain. 4Department of
Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.
5Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
6University Hospitals and KU Leuven, Leuven, Belgium. 7Department of Internal
Medicine, Seoul National University College of Medicine, Seoul, Republic of
Korea (South). 8Department of Internal Medicine, Yonsei Cancer Center, Yonsei
University College of Medicine, Seoul, Republic of Korea (South). 9Department
of Gastroenterological Chemotherapy, The Cancer Institute Hospital of JFCR,
Tokyo, Japan. 10Department of Oncology, Debreceni Egyetem Klinikai K€ozpont,
Debrecen, Hungary. 11Department of Hematology, Oncology, Linkou Chang
Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan.
12Department of Medical Oncology, UCL Cancer Institute, London, United
Kingdom. 13Department of Hematology, Oncology, and Tumor Immunology,
Charite–University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany.
14Deparment of Tumor Diseases, Institut f€ur Klinisch-Onkologische, Frankfurt,
Germany. 15Department of Hematology and Medical Oncology, Pontificia
Universidad Catolica de Chile, Santiago, Chile. 16Department of Medical Oncol-
ogy, Merck & Co., Inc., Kenilworth, New Jersey. 17Department of Medical
Oncology and Therapeutics Research, City of Hope Comprehensive Cancer
Center, Duarte, California.
Corresponding Author: Zev A. Wainberg, Division of Hematology/Oncology,
David Geffen School of Medicine at UCLA, 2825 Santa Monica Blvd, Suite 200,
Santa Monica, CA, 90404. Phone: 310-633-8400; Fax: 310-586-0841;
E-mail: zwainberg@mednet.ucla.edu
Clin Cancer Res 2021;27:1923–31
doi: 10.1158/1078-0432.CCR-20-2980
2021 American Association for Cancer Research.
AACRJournals.org | 1923
on August 8, 2021. © 2021 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst January 14, 2021; DOI: 10.1158/1078-0432.CCR-20-2980 
protein repair–deficient (dMMR) gastric cancer. On the basis of results
fromKEYNOTE-059, pembrolizumab is also approved as third-line or
later therapy for patients with tumors that have a PD-L1 combined
positive score (CPS) ≥ 1 (7). The ability of PD-L1 expression to
predict response to immune checkpoint inhibitors beyond the
approved use of third-line pembrolizumab for gastric cancer
expressing CPS ≥ 1 remains unclear.
Pembrolizumab has demonstrated antitumor activity in patients
with PD-L1–positive advanced gastric or gastroesophageal junction
(GEJ) cancer in phase II and III trials (8–10). In cohort 1 of the global,
single-arm, multicohort, phase II KEYNOTE-059 study, patients with
advanced gastric or GEJ cancer whose disease progressed after ≥2 lines
of therapy received pembrolizumab monotherapy (8). Among the 148
patients with CPS ≥ 1 tumors that were either microsatellite stable or
had unknown MMR/dMMR status, 23 patients had a response, for an
objective response rate (ORR) of 15.5%. The median duration of
response (DOR) among these patients was 16.3 months (range,
1.6þ to 17.3þ), and safety was manageable. Although the ORR was
higher in patients with PD-L1–positive tumors (15.5%) than in
patients with PD-L1–negative tumors (6.4%), the responses observed
in the PD-L1–negative population indicated an incomplete separation
of responders from nonresponders based on CPS ≥ 1 (8).
In the randomized, open-label, phase III KEYNOTE-061 study,
patients with advanced gastric or GEJ cancer whose disease progressed
after first-line therapy received pembrolizumab or paclitaxel (9).
Among the 395 patients with CPS ≥ 1 tumors, pembrolizumab did
not significantly prolong survival compared with paclitaxel [median
OS, 9.1 vs. 8.3 months; HR, 0.82; 95% confidence interval (CI), 0.66–
1.03; one-sided P¼ 0.0421]. Although there was also no improvement
in progression-free survival (PFS) or response rates, pembrolizumab
monotherapy did offer more durable responses and a favorable safety
profile compared with paclitaxel.
The randomized phase III KEYNOTE-062 study enrolled patients
with advanced gastric or GEJ cancer who had not previously received
therapy for advanced disease (10). Among the 506 patients with
CPS ≥ 1 tumors, OS with pembrolizumab was noninferior to that
with cisplatin plus 5-fluorouracil (5-FU) or capecitabine (HR, 0.91;
99.2% CI, 0.69–1.18; prespecified noninferiority margin, 1.2).
Pembrolizumab did not improve PFS or ORR but demonstrated a
better tolerability profile than chemotherapy.
The predictive value of PD-L1 in gastric cancer is unclear given that
multiple studies with immune checkpoint inhibitors other than pem-
brolizumab have demonstrated similar responses in patients regardless
of PD-L1 status. In addition, the absence of a standard PD-L1 IHC
assay and scoring method across studies makes cross-study compar-
isons difficult. In the phase I/II CheckMate-032 study of patients with
chemotherapy-refractory advanced esophagogastric cancer, responses
were observed with nivolumab alone and with nivolumab in combi-
nation with ipilimumab regardless of PD-L1 status [defined as tumor
proportion score (TPS) with a cutoff of 1% using PD-L1 IHC 28–8
pharmDx (Agilent Technologies; ref. 11]. Response rates were numer-
ically higher in patients with PD-L1–positive tumors, but the sample
sizes were small. The phase III ATTRACTION-2 study randomly
assigned patients with advanced gastric or GEJ cancer who had
previously received two or more lines of therapy to receive nivolumab
or placebo (12). In an exploratory analysis evaluating PD-L1 expres-
sion (defined as TPS with a cutoff of 1%) and OS, median OS was
numerically higher with nivolumab than with placebo regardless of
PD-L1 positivity. Outcomes based onPD-L1 statuswere also evaluated
with avelumab in patients with gastric cancer in the phase Ib JAVELIN
Solid Tumor trial (13), the phase III JAVELIN Gastric 300 trial (14),
and the phase III JAVELIN Gastric 100 trial (15). There were no
significant differences in outcomes among patients with PD-L1–
positive or PD-L1–negative tumors. For all three studies, PD-L1
positive was defined as ≥1% of tumor cells using PD-L1 IHC 73–10
pharmDx. However, exploratory analysis using 22C3 pharmDx sug-
gested a survival benefit with maintenance avelumab over chemother-
apy in patients with CPS ≥ 1 tumors (HR, 0.72; 95% CI, 0.49–1.05;
refs. 15 and 16).
In addition to measuring PD-L1 expression on tumor cells and
before the development of CPS, pembrolizumab studies assessed
response by mononuclear inflammatory cell density score (MIDS).
The CheckMate-032, ATTRACTION-2, and JAVELINGastric studies
did not evaluate MIDS, which might have provided different results,
highlighting the need to continue exploring patient subgroups likely to
respond to PD-1/PD-L1 inhibitors.
Among the limited PD-L1 data available for patients with
gastric or GEJ cancer, the open-label phase Ib KEYNOTE-012 study
(NCT01848834) evaluated the antitumor activity of pembrolizumab in
patients with PD-L1–positive recurrent ormetastatic adenocarcinoma
of the stomach or GEJ (17). PD-L1 expression was measured in 35
patients with available biopsy samples at baseline using TPS and
MIDS. When response was evaluated using TPS, ORR was 24% for
patients with TPS 0%, 0% for patients with TPS 1% to 49%, and 33% for
patients with TPS ≥50%. When response was evaluated using MIDS,
ORR was 0% for MIDS 0, 25% for MIDS 1, 12% for MIDS 2, 44% for
MIDS 3, and 0% forMIDS 4. Although conclusions are limited because
of the small numbers of patients, these findings do not demonstrate an
association between response and high PD-L1 expression using TPS
though there may be an association between highMIDS and response.
The study provided evidence of the importance of measuring PD-L1
expression in immune cells, as opposed to tumor cells exclusively, in
patients with gastric cancer based on analysis of the results and on the
use of CPS. In the CheckMate-649 study in patients with gastric or GEJ
cancer or esophageal adenocarcinoma, nivolumab plus chemotherapy
provided statistically significant improvements in OS and PFS com-
pared with chemotherapy alone in patients with CPS ≥ 5 tumors (18).
A statistically significant OS benefit was also shown in patients with
CPS ≥ 1 tumors and in the all-randomly assigned population, showing
an enrichment of OS benefit as the CPS cutoff increased (18).
Translational Relevance
Pembrolizumab monotherapy demonstrated a clinically mean-
ingful survival benefit and durable antitumor activity in patients
with PD-L1 combined positive score (CPS) ≥10 gastric or gastro-
esophageal junction cancer fromKEYNOTE-059 cohort 1 (n¼ 46;
third-line or later setting), KEYNOTE-061 (n ¼ 53; second-line
setting), and KEYNOTE-062 (n ¼ 92; first-line setting). We
observed numerically higher overall survival medians, response
rates, and durations of response with pembrolizumab monother-
apy than with chemotherapy in patients whose tumors expressed
CPS ≥ 10 across lines of therapy. Responsiveness to immune
checkpoint inhibitors and the role of pembrolizumab in the
treatment paradigm of gastric cancer are still being determined,
and this study adds to the existing body of evidence that the
immunohistochemical PD-L1 CPS is one clinically relevant bio-
marker that can lead to improved clinical efficacy.
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A recent meta-analysis of randomized controlled trials of PD-1/
PD-L1 inhibitors in patients with advanced solid tumors, including
three trials in patients with gastric or GEJ cancer, suggested that
enriching for PD-L1 status by increasing the minimum propor-
tion of stained cells can increase efficacy in a dose–response
relationship (19). On the basis of the experience with pembrolizu-
mab in gastric cancer clinical trials, CPS ≥ 10 was chosen for further
evaluation in this analysis to better delineate the specificity of
CPS as a predictor of clinical outcomes with pembrolizumab mono-
therapy. Herein, we characterize clinical outcomes with pem-
brolizumab monotherapy across lines of therapy in patients with
CPS ≥ 10 advanced gastric or GEJ cancer by analyzing patients
with CPS ≥ 10 tumors enrolled in cohort 1 of KEYNOTE-059




The designs of KEYNOTE-059 cohort 1, KEYNOTE-061, and
KEYNOTE-062 have been described previously (8–10). In brief, all
three trials evaluated the efficacy of pembrolizumab 200 mg admin-
istered intravenously every 3 weeks for up to 35 cycles (2 years) for
locally advanced unresectable or metastatic gastric or GEJ adenocar-
cinoma. InKEYNOTE-059, patients were enrolled regardless of PD-L1
expression status. InKEYNOTE-061, patients were randomly assigned
1:1 to receive pembrolizumab monotherapy or standard-dose pacli-
taxel administered intravenously. Initially, patients were enrolled
regardless of PD-L1 expression status, but enrollment was then
restricted to those with CPS ≥ 1 tumors (9). In KEYNOTE-062,
patients were randomly assigned (1:1:1) to receive pembrolizumab
monotherapy, pembrolizumab plus chemotherapy (standard-dose
cisplatin plus 5-FU or capecitabine administered intravenously or
orally, respectively), or placebo plus chemotherapy (hereafter referred
to as chemotherapy); patients were required to have CPS ≥ 1
tumors (10). The current analysis of KEYNOTE-062 includes only
those patients enrolled in the pembrolizumab monotherapy and
chemotherapy groups.
PD-L1 expression was assessed in archival or newly collected tumor
samples using PD-L1 IHC 22C3 pharmDx (Agilent Technologies;
refs. 8–10) andwasmeasured using CPS [defined as the number of PD-
L1–staining cells (tumor cells, lymphocytes, macrophages) as a pro-
portion of the total number of tumor cells multiplied by 100; ref. 20].
Samples were not reanalyzed for this analysis. For all three trials, the
primary analysis populations were patients with CPS ≥ 1 tumors.
Analysis of outcomes in patients with CPS ≥ 10 was post hoc for
KEYNOTE-059 and KEYNOTE-061 but was part of the prespecified
primary analysis for KEYNOTE-062.
The study protocols and all amendments were approved by the
institutional review board or ethics committee at each participating
institution. The studies were conducted in accordance with the
protocol and its amendments and with Good Clinical Practice guide-
lines. All patients provided written informed consent before
enrollment.
Outcomes and statistical considerations
For the current analysis, we evaluated clinical outcomes in all
patients with CPS ≥ 10 tumors who received ≥1 dose of study drug.
Results were analyzed for each of the trials separately (i.e., results were
not pooled across trials). Efficacy endpoints included OS, PFS, ORR
[complete response (CR) plus partial response (PR)], and DOR.
Response was assessed by central review per RECIST v1.1. The
Kaplan–Meier method was used to calculate OS, PFS, and DOR. HRs
and their associated 95% CIs were calculated using stratified Cox
proportional hazards models with the Efron method of tie handling.
In KEYNOTE-059, ORR was calculated using the Clopper–Pearson
method. In KEYNOTE-061 and KEYNOTE-062, treatment differ-
ences in OS and PFS were assessed using the log-rank test with HRs
estimated using a stratified Cox regression model. Response rate was
compared using theMiettinen andNurminenmethod. In KEYNOTE-
062, the prespecified hypotheses included OS analysis of pembroli-
zumab versus chemotherapy in patients with PD-L1 CPS ≥ 10 with a
planned enrollment for 80% power to detect a HR of 0.58 at alpha ¼
0.75% (one-sided). Full details of the statistical analysis have been
published previously (10).
Data cut-off dates for this analysis were August 8, 2018, for
KEYNOTE-059, October 26, 2017, for KEYNOTE-061, and March
26, 2019, for KEYNOTE-062.
All three trials are registered withClinicalTrials.gov [NCT02335411
(KEYNOTE-059), NCT02370498 (KEYNOTE-061), NCT02494583
(KEYNOTE-062)].
Data sharing
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
Kenilworth, NJ (MSD) is committed to providing qualified scientific
researchers access to anonymized data and clinical study reports from
the company’s clinical trials for the purpose of conducting legitimate
scientific research. MSD is also obligated to protect the rights and
privacy of trial participants and, as such, has a procedure in place for
evaluating and fulfilling requests for sharing company clinical trial
data with qualified external scientific researchers. The MSD data-
sharing website (available at: http://engagezone.msd.com/ds_docu
mentation.php) outlines the process and requirements for submitting
a data request. Applicationswill be promptly assessed for completeness
and policy compliance. Feasible requests will be reviewed by a com-
mittee of MSD subject matter experts to assess the scientific validity of
the request and the qualifications of the requestors. In line with data
privacy legislation, submitters of approved requests must enter into a
standard data-sharing agreement with MSD before data access is
granted. Data will bemade available for request after product approval
in the United States and European Union or after product develop-
ment is discontinued. There are circumstances that may prevent MSD
from sharing requested data, including country or region-specific
regulations. If the request is declined, it will be communicated to the
investigator. Access to genetic or exploratory biomarker data requires a
detailed, hypothesis-driven statistical analysis plan that is collabora-
tively developed by the requestor and MSD subject matter experts;
after approval of the statistical analysis plan and execution of a data-
sharing agreement, MSD will either perform the proposed analyses
and share the results with the requestor or will construct biomarker
covariates and add them to a file with clinical data that is uploaded to
an analysis portal so that the requestor can perform the proposed
analyses.
Results
All patients enrolled in KEYNOTE-059, KEYNOTE-061, and KEY-
NOTE-062 had evaluable tumor samples for PD-L1 status with the
exception of 2 patients each in KEYNOTE-059 cohort 1 and KEY-
NOTE-061; 31% (46/148), 18% (108/592), and 36% (182/506), respec-
tively, had CPS ≥ 10 tumors (Table 1). Follow-up duration is reported
in Table 1. Baseline characteristics for patients with CPS ≥ 10 tumors
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were generally comparable between the pembrolizumab and chemo-
therapy groups in KEYNOTE-061 and KEYNOTE-062 (Table 2).
OS and PFS in the CPS ≥ 10 population
In KEYNOTE-059, median OS was 8 months (95% CI, 5.8–11.1).
OS rates were 33% at 12 months and 15% at 24 months (Fig. 1A). In
KEYNOTE-061, median OS was 10 months (95% CI, 5.9–17.3) with
pembrolizumab and 8 months (95% CI, 5.1–9.9) with chemotherapy
(HR, 0.64; 95% CI, 0.41–1.02). The OS rates for pembrolizumab and
chemotherapy were 45% versus 23% at 12months and 35% versus 18%
at 18 months, respectively (Fig. 1B). In KEYNOTE-062, median OS
was 17months (95%CI, 9.1–23.1)with pembrolizumab and11months
(95% CI, 8.5–13.8) with chemotherapy (HR 0.69; 95% CI, 0.49–0.97).
The OS rates for pembrolizumab and chemotherapy were 57% versus
47% at 12 months and 39% versus 22% at 24 months, respectively
(Fig. 1C). Kaplan–Meier curves showed improved OS in the CPS ≥ 10
population compared with the CPS ≥ 1 population from the original
studies (Fig. 1A–C).
In KEYNOTE-059, median PFS was 2 months (95% CI, 2.0–
3.4; Fig. 2A). In KEYNOTE-061, median PFS was 3 months (95%
CI, 1.4–3.1) with pembrolizumab and 3months (95%CI, 2.7–4.1) with
chemotherapy (HR, 0.86; 95% CI, 0.56–1.33; Fig. 2B). In KEYNOTE-
062,median PFSwas 3months (95%CI, 1.6–5.4) with pembrolizumab
and 6months (95%CI, 5.4–6.9) with chemotherapy (HR, 1.09; 95%CI,
0.79–1.49; Fig. 2C). Kaplan–Meier curves of PFS in the CPS ≥ 10
population compared with the CPS ≥ 1 population from the original
studies are shown in Fig. 2A–C.
Response in the CPS ≥ 10 population
In KEYNOTE-059, the confirmed ORR was 17% (n ¼ 8); 1 patient
achieved CR and 7 achieved PR (Table 3). The median DOR was
21 months (range, 3þ to 35þ; Fig. 3A); five responders (71%) had a
response duration≥6months. InKEYNOTE-061, confirmedORRwas
25% (n¼ 13) for pembrolizumab-treated patients; 5 patients achieved
CR and 8 PR (Table 3). In chemotherapy-treated patients, the ORR
was 9% (n¼ 5); 1 patient achieved CR and 4 achieved PR. The median
DOR was not reached (range, 4 to 26þ months) for pembrolizumab
and was 7 months (range, 3–7) for chemotherapy (Fig. 3B); 10
responders (77%) treated with pembrolizumab and one responder
(53%) treated with chemotherapy had a response duration ≥6months.
Table 1. Incidence of PD-L1–positive tumors and follow-up of patients with CPS ≥ 10 tumors.
KEYNOTE-059 KEYNOTE-061 KEYNOTE-062
Incidence Pembrolizumab Pembrolizumab Chemotherapy Pembrolizumab Chemotherapy
Patients with CPS ≥ 1, n/N (%) 148/259 (57) 196/296 (66) 199/296 (67) 256/256 (100) 250/250 (100)
Patients with CPS ≥ 10, n/N (%) 46/259 (18) 53/296 (18) 55/296 (19) 92/256 (36) 90/250 (36)
Median follow-up (range), months 6 (<1–38) 10 (<1–28) 8 (1–27) 17 (<1–38) 11 (1–35)
Abbreviations: CPS, combined positive score; PD-L1, programmed death ligand 1.













Median age, years (range) 63 (30–79) 66 (35–79) 60 (37–76) 59 (20–81) 65 (31–82)
Male, n (%) 34 (74) 35 (66) 35 (64) 64 (70) 64 (71)
Race, n (%)
White 38 (83) 34 (64) 38 (69) 58 (63) 58 (64)
Asian 3 (7) 17 (32) 13 (24) 27 (29) 23 (26)
Black 1 (2) 1 (2) 1 (2) 2 (2) 1 (1)
American Indian or Alaska
Native
0 1 (2) 2 (4) 3 (3) 5 (6)
Multiple 1 (2) 0 1 (2) 1 (1) 3 (3)
Missing 3 (7) 0 0 0 0
ECOG PS, n (%)
0 25 (54) 24 (45) 24 (44) 47 (51) 34 (38)
1 21 (46) 29 (55) 31 (56) 45 (49) 56 (62)
No. of previous therapies for metastatic disease, n (%)
2 21 (46) — — — —
3 14 (30) — — — —
4 8 (17) — — — —
≥5 3 (7) — — — —
Tumor site, n (%)a
Stomach 22 (48) 35 (66) 35 (64) 68 (74) 69 (77)
GEJ 23 (50) 18 (34) 20 (36) 24 (26) 20 (22)
MSI-H, n (%) 2 (4) 8 (15) 5 (9) 11 (12) 10 (11)
Abbreviations: CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; GEJ, gastroesophageal junction. MSI-H,
microsatellite instability-high.
aIn KEYNOTE-062, one patient (1.1%) had a tumor site of “missing.”
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Kaplan–Meier estimates of OS in patients with CPS ≥ 1 and CPS ≥ 10 tumors.
A, Patients receiving third-line and later pembrolizumab in KEYNOTE-059
cohort 1. B, Patients receiving second-line pembrolizumab or chemotherapy in
KEYNOTE-061. C, Patients receiving first-line pembrolizumab or chemotherapy




















































































































































































































































B Pembrolizumab, CPS ≥10 
Chemotherapy, CPS ≥10 
Pembrolizumab, CPS ≥1
Chemotherapy, CPS ≥1
Pembrolizumab, CPS ≥10 
Pembrolizumab, CPS ≥1 
Pembrolizumab, CPS ≥10




Kaplan–Meier estimates of PFS in patients with CPS ≥ 1 and CPS ≥ 10 tumors.
A, Patients receiving third-line and later pembrolizumab in KEYNOTE-059
cohort 1. B, Patients receiving second-line pembrolizumab or chemotherapy
in KEYNOTE-061. C, Patients receiving first-line pembrolizumab or chemo-
therapy in KEYNOTE-062. CPS, combined positive score; PFS, progression-
free survival.
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In KEYNOTE-062, confirmed ORR was 25% (n ¼ 23) for pembro-
lizumab-treated patients; 7 patients achieved CR and 16 achieved PR
(Table 3). In chemotherapy-treated patients, the ORR was 38% (n ¼
34); 4 patients achieved CR and 30 achieved PR. Themedian DORwas
19 months (range, 1þ to 34þ) for pembrolizumab and 7 months
(range, 2þ to 30þ) for chemotherapy (Fig. 3C); 18 responders (82%)
treated with pembrolizumab and 16 responders (53%) treated with
chemotherapy had a response duration ≥6 months. Kaplan–Meier
curves showed DOR in the CPS ≥ 10 population compared with the
CPS ≥ 1 population from the original studies.
Discussion
In the primary analysis of patients with CPS ≥ 1 gastric or GEJ
cancer who were enrolled in KEYNOTE-059 cohort 1, KEYNOTE-
061, and KEYNOTE-062, pembrolizumab monotherapy demonstrat-
ed promising antitumor activity. In KEYNOTE-061 and KEYNOTE-
062, pembrolizumab was associated with an improved safety profile,
but it did not significantly improve survival outcomes compared with
chemotherapy (8–10). The current analysis in patients with CPS ≥ 10
tumors revealed durable responses and elongation of the tails of the
Kaplan–Meier OS curves with pembrolizumab monotherapy across
lines of therapy. However, pembrolizumab monotherapy did not
numerically improve PFS in this analysis of KEYNOTE-061 or KEY-
NOTE-062 or ORR in KEYNOTE-062 compared with chemotherapy.
The relationship between OS and PFS in clinical trials of immune
checkpoint inhibitors has been investigated in several tumor types,
including gastric cancer; differences in PFS and OS benefit as well as
direction of outcomes are likely attributable to the mechanism of
action, specific disease, and population under study (21).
In addition to other factors including MSI and HER2 status, PD-L1
expression can provide important guidance for patient selection in
clinical practice and is used to select patients eligible for pembrolizu-
mab therapy. On the basis of a recent meta-analysis showing an
expression–response relationship between PD-L1 and OS, we evalu-
ated whether an increase in PD-L1 positivity fromCPS ≥ 1 to CPS ≥ 10
resulted in improved responses to pembrolizumab (19). In comparing
the current analysis of CPS ≥ 10 tumors, in which patient numbers are
small, with previously reported data in patients with CPS ≥ 1 tumors,
we observed numerically higher median OS, ORR, and DOR with
pembrolizumab therapy by increasing the CPS cutoff from ≥1 to ≥10.
In KEYNOTE-059, median OS increased from 6 to 8 months, and the
12-monthOS rate increased from24% to 33%, theORR increased from
16% to 17%, and the DOR increased from 16 to 21 months (8). In
KEYNOTE-061, median OS increased from 9 to 10 months, and the
12-month OS rate increased from 40% to 45%, the 18-month OS rate
increased from 26% to 35%, the ORR increased from 16% to 25%, and
the DOR increased from 18 months to not reached (9, 22). In
KEYNOTE-062, median OS increased from 11 to 17 months, and
the 12-month OS rate increased from 47% to 57%, the 24-month OS
rate increased from 27% to 39%, the ORR increased from 15% to 25%,
and the DOR increased from 14 to 19months (10). In KEYNOTE-061,
theHR forOS decreased from 0.82 for CPS ≥ 1 to 0.64 for CPS ≥ 10 (9),
and in KEYNOTE-062, theHR for OS decreased from 0.91 for CPS ≥ 1
to 0.69 for CPS ≥ 10 (10). In KEYNOTE-062, the combination of
pembrolizumab and chemotherapy was not superior to chemotherapy
for OS in patients with CPS ≥ 1 or CPS ≥ 10 tumors (10). Thus,
increasing the CPS cutoff to CPS ≥ 10 in patients with gastric or GEJ
cancer may provide greater treatment benefit for patients eligible to
receive pembrolizumab monotherapy.
The clinical benefit of using higher PD-L1 cutoffs with pembroli-
zumab has also been evaluated in other tumor types. Evidence from the
phase III KEYNOTE-181 study in patients with advanced/metastatic
esophageal cancer demonstrated a significant benefit with a high CPS
cutoff. Among 222 patients with CPS ≥ 10 tumors, second-line
pembrolizumab monotherapy significantly improved OS versus
chemotherapy (HR, 0.69; 95% CI, 0.52–0.93; P ¼ 0.0074; ref. 23).
In the phase III KEYNOTE-048 trial in patients with untreated
locally incurable recurrent or metastatic head and neck squamous
cell carcinoma, pembrolizumab monotherapy demonstrated a
greater survival benefit than cetuximab plus chemotherapy in
the population with CPS ≥ 20 tumors (HR, 0.61; 95% CI, 0.45–
0.83; P ¼ 0.0007) than in the population with CPS ≥ 1 tumors (HR,
0.78; 95% CI, 0.64–0.96; P ¼ 0.0086; ref. 24). In the single-arm
phase II KEYNOTE-052 study in patients with locally advanced and
unresectable or metastatic urothelial cancer, response to pembro-
lizumab monotherapy increased with increasing CPS cutoff (CPS ≥
1, 11%; CPS > 1 to <10, 20%; CPS ≥ 10, 39%; ref. 25). In patients
with advanced recurrent ovarian cancer enrolled in the phase II
KEYNOTE-100 study, higher PD-L1 expression also correlated
with higher response to pembrolizumab monotherapy (CPS ≥ 1,
5.7%; CPS ≥ 10, 10.0%; ref. 26).
Limitations of the current analysis include the post hoc nature of
KEYNOTE-059 cohort 1 and KEYNOTE-061 and the small patient












ORR, n (%) 8 (17) 13 (25) 5 (9) 23 (25) 34 (38)
CR 1 (2) 5 (9) 1 (2) 7 (8) 4 (4)
PR 7 (15) 8 (15) 4 (7) 16 (17) 30 (33)
SD 9 (20) 12 (23) 28 (51) 23 (25) 39 (43)
PD 24 (52) 23 (43) 11 (20) 29 (32) 8 (9)
Not availablea 5 (11) 5 (9) 11 (20) 17 (19) 9 (10)
Median time to response, months,
(range)
2 (2–4) 2 (1–3) 2 (1–4) 1 (1–7) 2 (1–7)
Median DOR, months, (range) 21 (3þ to 35þ) NR (4 to 26þ) 7 (3 to 7) 19 (1þ to 34þ) 7 (2þ to 30þ)
Abbreviations: CI, confidence interval; CPS, combined positive score; CR, complete response; DOR, duration of response; NR, not reached; PD, progressive disease;
PR, partial response; SD, stable disease.
aIndicates patients without an evaluable assessment or patients who had a baseline assessment but no postbaseline assessment as of the data cut-off date (due to
missing, discontinuing, or death before the first postbaseline assessment).
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numbers within each subgroup. Furthermore, biomarker enrichment
can predict response, but prevalence can decrease with higher CPS
enrichment. Taken together, definitive conclusions cannot be made
from this analysis.
In this analysis, these data suggest that pembrolizumab monother-
apy given as first-line (KEYNOTE-062), second-line (KEYNOTE-
061), and third-line and later (KEYNOTE-059) therapy showed a
clinically meaningful median and long-term survival benefit in
patients with CPS ≥ 10 gastric or GEJ tumors and more durable
responses compared with chemotherapy. This study adds to the
existing body of evidence that the immunohistochemical PD-L1 CPS
is one clinically relevant biomarker that can lead to improved clinical
efficacy and validates the importance of refining the PD-L1 CPS
biomarker companion diagnostic as we attempt to define the optimal
role of pembrolizumab in gastric cancer. Although evidence from the
current analysis and in other tumor types has validated scoring of PD-
L1 expression using tumor and immune cells (i.e., CPS) to predict
response to pembrolizumab, large and prospective trials are needed to
validate the optimal CPS cutoff for patients with gastric or GEJ cancer.
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Figure 3.
Kaplan–Meier estimates of DOR in patients with CPS ≥ 1 and CPS ≥ 10 tumors.
A, Patients receiving third-line and later pembrolizumab in KEYNOTE-059
cohort 1. B, Patients receiving second-line pembrolizumab or chemotherapy
in KEYNOTE-061. C, Patients receiving first-line pembrolizumab or chemo-
therapy in KEYNOTE-062. CPS, combined positive score; DOR, duration of
response.
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